The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

Baxter International Reports Q4 Revenue Growth Amid Sharp Earnings Decline and Weak 2026 Outlook

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Baxter International (BAX) reported its fourth-quarter 2025 financial results, showing an 8% increase in sales to $2.97 billion. Despite the revenue growth, the company faced significant financial pressure, with adjusted diluted EPS from continuing operations falling by 24%. A substantial loss was also recorded under GAAP standards, highlighting ongoing operational challenges. Looking ahead, Baxter issued a cautious guidance for 2026, projecting roughly flat sales and a further decline in adjusted earnings. The company is currently undergoing a board refresh to address these headwinds, while analysts maintain a neutral stance following the report. Investors are closely monitoring how these structural changes will impact the firm's long-term recovery in the healthcare sector.